Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis
Latest ClaritX AI analysis ·
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepati
| Metric | Value |
|---|---|
| Price | $219.72 |
| Market cap | $29.4B |
| Sector | Healthcare |
| Industry | Biotechnology |
| ClaritX AI score | 40/100 |
| Price/Book | 21.62 |
| Beta | 0.30 |
AI verdict
The investment thesis for Alnylam Pharmaceuticals (NASDAQ: ALNY) remains defined by an agonizing conflict between exceptional underlying fundamental profitability and a profoundly damaged technical and psychological momentum profile. It is critical to recognize the stock's exact positioning: currently trading at $219.72, Alnylam is languishing a devastating 55.66% below its 52-week high of $495.55. Despite possessing a remarkably low beta of 0.3, a metric traditionally viewed as a defensive shield against broad market volatility, this massive structural drawdown unequivocally proves that statistical non-correlation offers zero protection against idiosyncratic corporate shocks. The severe downward revision of the 2026 TTR franchise revenue outlook, collateral damage from competitor trial failures, and the newly announced October 2 securities fraud investigation have violently re-rated the stock, trapping it in an unrelenting downtrend well below its 20-day, 50-day, and 200-day moving averages. Despite the catastrophic loss of market capitalization, the core business engine remains utterly pristine, highlighted by an elite 93.61% Return on Equity, a 79.72% gross margin, and a fortress balance sheet boasting $24.83 in cash per share. However, trading at a still-demanding 36.02 trailing P/E ratio, the stock lacks a true deep-value margin of safety to absorb the current wave of negative news. Alnylam is a phenomenal, highly profitable enterprise currently paralyzed by a toxic cha
What this score has been worth
ClaritX scores ALNY 40 out of 100 (snapshot 2026-10-05).
Every ClaritX analysis is scored first and judged only on what the stock did afterwards. Across the 117 analyses that scored in the 0-49 band, the average forward return was -4.2% with a 32% win rate, -9.0pp against the S&P 500. That is a measured tendency across many names, not a forecast for ALNY — roughly 68% of stocks in this band still lost money.
The full band-by-band table, including the bands that lost, is on the AI Rank Report; the live strategy arms behind it are on the AI Track Record, losses published.